# Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

> **NCT04908475** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 352 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT04908475
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-09
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908475, "Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04908475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*